Lilly Launches Cymbalta Antidepressant

[Guest guest]

http://www.forbes.com/home/feeds/ap/2004/08/24/ap1516993.html

The money machine keeps on rolling.

Associated Press

Lilly Launches Cymbalta Antidepressant

08.24.2004, 01:11 PM

Pharmaceutical company Eli Lilly & Co. said Tuesday that it launched the

antidepressant Cymbalta and expects the drug to be available in more than 80

percent of U.S. pharmacies by Aug. 30.

The Food and Drug Administration approved Cymbalta for the treatment of major

depression in adults on Aug. 3. Lilly said more than half of the nation's

pharmacies have stocked the drug, and it expects Cymbalta to be available in

more than 44,000 pharmacies by the end of the month. Cymbalta's average

wholesale price will be $2.85 for 60 milligrams, the usual daily dose, which

Lilly called comparable to competitors.

Cymbalta is Lilly's most recent foray into antidepressants since creating the

market with Prozac, the only antidepressant approved for use in children and

teenagers in the United States. Cymbalta has been proven effective at treating

both the physical and emotional symptoms of depression, rather than just the

physical effects that most antidepressant drugs target.

The drug is also the first antidepressant released since the FDA began studying

the effects of antidepressants in children last year and measuring whether the

drugs increase the risk of suicidal tendencies. Following Cymbalta's approval,

the agency concluded that the drug was not responsible for the suicide of a

19-year-old woman who was taking part in a Cymbalta clinical trial.

Shares of Lilly were up 26 cents, or 0.4 percent, at $64.66 in afternoon trading

on the New York Stock Exchange.

[Guest guest]

http://www.forbes.com/home/feeds/ap/2004/08/24/ap1516993.html

The money machine keeps on rolling.

Associated Press

Lilly Launches Cymbalta Antidepressant

08.24.2004, 01:11 PM

Pharmaceutical company Eli Lilly & Co. said Tuesday that it launched the

antidepressant Cymbalta and expects the drug to be available in more than 80

percent of U.S. pharmacies by Aug. 30.

The Food and Drug Administration approved Cymbalta for the treatment of major

depression in adults on Aug. 3. Lilly said more than half of the nation's

pharmacies have stocked the drug, and it expects Cymbalta to be available in

more than 44,000 pharmacies by the end of the month. Cymbalta's average

wholesale price will be $2.85 for 60 milligrams, the usual daily dose, which

Lilly called comparable to competitors.

Cymbalta is Lilly's most recent foray into antidepressants since creating the

market with Prozac, the only antidepressant approved for use in children and

teenagers in the United States. Cymbalta has been proven effective at treating

both the physical and emotional symptoms of depression, rather than just the

physical effects that most antidepressant drugs target.

The drug is also the first antidepressant released since the FDA began studying

the effects of antidepressants in children last year and measuring whether the

drugs increase the risk of suicidal tendencies. Following Cymbalta's approval,

the agency concluded that the drug was not responsible for the suicide of a

19-year-old woman who was taking part in a Cymbalta clinical trial.

Shares of Lilly were up 26 cents, or 0.4 percent, at $64.66 in afternoon trading

on the New York Stock Exchange.

[Guest guest]

http://www.forbes.com/home/feeds/ap/2004/08/24/ap1516993.html

The money machine keeps on rolling.

Associated Press

Lilly Launches Cymbalta Antidepressant

08.24.2004, 01:11 PM

Pharmaceutical company Eli Lilly & Co. said Tuesday that it launched the

antidepressant Cymbalta and expects the drug to be available in more than 80

percent of U.S. pharmacies by Aug. 30.

The Food and Drug Administration approved Cymbalta for the treatment of major

depression in adults on Aug. 3. Lilly said more than half of the nation's

pharmacies have stocked the drug, and it expects Cymbalta to be available in

more than 44,000 pharmacies by the end of the month. Cymbalta's average

wholesale price will be $2.85 for 60 milligrams, the usual daily dose, which

Lilly called comparable to competitors.

Cymbalta is Lilly's most recent foray into antidepressants since creating the

market with Prozac, the only antidepressant approved for use in children and

teenagers in the United States. Cymbalta has been proven effective at treating

both the physical and emotional symptoms of depression, rather than just the

physical effects that most antidepressant drugs target.

The drug is also the first antidepressant released since the FDA began studying

the effects of antidepressants in children last year and measuring whether the

drugs increase the risk of suicidal tendencies. Following Cymbalta's approval,

the agency concluded that the drug was not responsible for the suicide of a

19-year-old woman who was taking part in a Cymbalta clinical trial.

Shares of Lilly were up 26 cents, or 0.4 percent, at $64.66 in afternoon trading

on the New York Stock Exchange.

[Guest guest]

http://www.forbes.com/home/feeds/ap/2004/08/24/ap1516993.html

The money machine keeps on rolling.

Associated Press

Lilly Launches Cymbalta Antidepressant

08.24.2004, 01:11 PM

Pharmaceutical company Eli Lilly & Co. said Tuesday that it launched the

antidepressant Cymbalta and expects the drug to be available in more than 80

percent of U.S. pharmacies by Aug. 30.

The Food and Drug Administration approved Cymbalta for the treatment of major

depression in adults on Aug. 3. Lilly said more than half of the nation's

pharmacies have stocked the drug, and it expects Cymbalta to be available in

more than 44,000 pharmacies by the end of the month. Cymbalta's average

wholesale price will be $2.85 for 60 milligrams, the usual daily dose, which

Lilly called comparable to competitors.

Cymbalta is Lilly's most recent foray into antidepressants since creating the

market with Prozac, the only antidepressant approved for use in children and

teenagers in the United States. Cymbalta has been proven effective at treating

both the physical and emotional symptoms of depression, rather than just the

physical effects that most antidepressant drugs target.

The drug is also the first antidepressant released since the FDA began studying

the effects of antidepressants in children last year and measuring whether the

drugs increase the risk of suicidal tendencies. Following Cymbalta's approval,

the agency concluded that the drug was not responsible for the suicide of a

19-year-old woman who was taking part in a Cymbalta clinical trial.

Shares of Lilly were up 26 cents, or 0.4 percent, at $64.66 in afternoon trading

on the New York Stock Exchange.